C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

C4X Discovery Holdings plc has licenced its oral  C4XD oral IL-17A inhibitor programme to Sanofi.

Increasing the efficiency of bioprocess workflows is key to stay competitive. The SciVario twin helps to develop and optimize processes in terms of time and cost efficiency. All critical process parameters can be precisely controlled directly at the controller’s touch screen. Regardless of the research segment, it is suitable for microbial and cell culture applications. The innovative bay-drawer system enables the system to flexibly adapt to unique requirements and changing processes. Eppendorf will offer updates with new functional modules, support for more, larger bioreactors, and additional software features to make the SciVario twin a future-proof solution.

Intravacc has announced positive data for its nasal SARS-CoV-2 vaccine that embeds the viral spike antigen in bacterial Outer Membrane Vesicles (OMV)